title: Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer.
abstract: BACKGROUND
  microRNA-26b (miR-26b) is reported to be downregulated in many human malignancies and function as a tumor suppressor. However, the roles of miR-26b expression in cervical cancer progression are unclear. The aim of this study was to investigate the clinicopathological or prognostic significance of miR-26b in human cervical cancer.
  
  
  METHODS
  A cohort of 88 paired of cervical cancer and the adjacent normal cervical epithelial tissues were collected. Quantitative RT-PCR (qRT-PCR) assay was used to detect the expression of miR-26b and its correlations with clinicopathological factors were statistically analyzed. Finally, the survival was assessed by the Kaplan-Meier method and proportional hazards model.
  
  
  RESULTS
  The expression level of miR-26b in cervical cancer tissues was significantly lower than that in the adjacent normal cervical tissues (P<0.001). Reduced miR-26b was observed to be significantly correlated with advanced FIGO stage, higher incidence of lymph node metastasis and recurrence of cervical cancer patients (P=0.002, 0.036 and 0.029, respectively). In addition, patients with low-miR-26b expression showed poorer recurrence-free survival (RFS) and overall survival (OS) than those with high-miR-26b expression (P=0.0043 and 0.0015, respectively). Furthermore, multivariate analyses demonstrated that low miR-26b expression was an independent prognostic factor for predicting the 5-year RFS and OS of cervical cancer patients (P=0.013 and 0.007, respectively).
  
  
  CONCLUSIONS
  Our results showed that reduced miR-26b was correlated with tumor development and poor prognosis in human cervical cancer. The status of miR-26b expression may be a potential prognostic biomarker for cervical cancer patients.
authors.affiliation: Department of Obstetrics and Gynecology, Guangzhou General Hospital of Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China.
authors.forename: Min
authors.initials: M
authors.lastname: Luo
authors.affiliation: Health Cadre Training Center, Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China.
authors.forename: Dongxiang
authors.initials: D
authors.lastname: Shen
authors.affiliation: Department of Pathology, Guangzhou General Hospital of Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.affiliation: Departemnt of Medical Research, Guangzhou General Hospital of Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China.
authors.forename: Jiang
authors.initials: J
authors.lastname: Xian
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; C528163:MIRN26 microRNA, human
keywords: Cervical cancer; microRNA-26b; overall survival; quantitative RT-PCR; recurrence-free survival